郭艺芳:2015年老年心血管病预防与康复领域进展盘点

2016-01-08 郭艺芳 国际循环

本年度内,老年心血管病预防与康复领域取得一系列重要进展。这些新的研究成果为老年心血管病防治策略的进一步完善提供了重要依据。高龄老年患者的降压强度虽然国内外各种指南对于老年人降压目标值的推荐有所不同,但总的来讲均趋于宽松。然而,在确定降压治疗强度时不应仅考虑年龄,一般健康状况也是决定降压治疗目标的重要因素。对于年龄较大但一般健康状况良好、无明显靶器官损害者,可以考虑较为严格的血压控制(如<140

本年度内,老年心血管病预防与康复领域取得一系列重要进展。这些新的研究成果为老年心血管病防治策略的进一步完善提供了重要依据。

高龄老年患者的降压强度

虽然国内外各种指南对于老年人降压目标值的推荐有所不同,但总的来讲均趋于宽松。然而,在确定降压治疗强度时不应仅考虑年龄,一般健康状况也是决定降压治疗目标的重要因素。对于年龄较大但一般健康状况良好、无明显靶器官损害者,可以考虑较为严格的血压控制(如<140/90 mm Hg),但对于一般健康状况较差、行动不便、认知功能障碍、独居、合并明显器质性疾患、身体衰弱者,其血压控制应更为宽松(<150/90 mm Hg甚至更高)。本年度内揭晓的PARTAGE研究显示,80岁以上、体质较弱者联合应用多种降压药物且收缩压<130 mm Hg的患者死亡的风险明显增高。该研究共纳入1127例80岁以上的老年患者,研究终点为随访2年内的全因死亡率。结果显示,服用2种以上降压药物且收缩压<130 mm Hg的受试者发生全因死亡的风险较其他患者增高81%。迄今关于高龄老年人降压治疗的随机化临床试验仅有HYVET研究,该研究结果表明,高龄人群同样可因积极的降压治疗显着获益。需注意,该研究除外了一般健康状况较差的体质虚弱老龄患者,因此其研究结论不能类推之所有老年人。另外一个需注意的问题是,很多男性老年患者常因良性前列腺增生服用α受体阻滞剂,此类药物可明显增加体位性低血压的风险。老年患者夜间起床时发生跌倒现象常见,与此类药物应用率较高有一定关系。现有研究提示,对于一般健康状况较好的患者,积极的降压治疗有助于更多改善患者预后;但对于一般健康状况较差的患者,应避免过于激进的血压控制。现行各种指南常基于年龄(>60岁、>65 岁、>70岁、>75岁、>80岁不等)做出更为宽松的降压目标值建议(一般<150/90 mm Hg),但在临床上除考虑年龄外,必须结合患者一般健康状况确定适度的降压治疗强度与适宜的治疗方案。

治疗老年高血压的新药

PARAMETER研究是应用血管紧张素受体脑啡肽酶抑制剂Entresto(即LCZ696)所进行的一项降压试验。共纳入454例≥60岁的单纯收缩期高血压患者(收缩压≥150 mm Hg,脉压≥60 mm Hg),随机分为两组,分别接受Entresto或奥美沙坦治疗。结果显示,治疗8周和12周后,Entresto在降低中心动脉收缩压、中心动脉脉压或肱动脉收缩压等方面的疗效均优于奥美沙坦,且前者可以更为有效的改善动脉弹性功能。这一研究表明,Entresto不仅在慢性心力衰竭治疗方面具有满意疗效,其在降压方面同样具有优秀表现。特别是该药可以更为有效的减小脉压并改善动脉弹性,完全契合老年高血压的临床特点,因而有望成为一种具有良好应用前景的新型降压药。

高龄老年人抗栓治疗的安全性

按照现行指南原则,伴有卒中中高危因素的心房颤动患者需接受抗栓治疗,以降低卒中风险。另一方面,接受冠状动脉介入治疗(PCI)术后的患者应接受双联抗血小板治疗,以降低复发性冠状动脉事件风险。联合应用抗凝药物与两种抗血小板药物时,患者发生出血性并发症的风险显着增高,高龄老年人尤为如此。由于现有随机化临床试验很少纳入高龄患者,因此关于此类患者的抗凝治疗策略尚缺乏足够的临床证据。新近,日本学者所完成的一项多中心研究对此进行了探讨,对认识高龄人群抗凝联合抗血小板治疗的获益风险比具有很大帮助。该研究共纳入接受PCI且伴有心房颤动的患者360例,其中≥80岁的患者77例,<80组患者283例。随访1年后结果显示,高龄组患者发生主要不良心血管与脑血管事件发生率显着高于较年轻组患者(16.9%对3.9%,P<0.001),两组出血事件发生率无显着差异。与仅接受双联抗血小板治疗的患者相比,联合应用口服抗凝剂与双联抗血小板治疗组患者累积心脑血管事件发生率有降低趋势,未达到统计学意义,但该组患者出血性并发症的风险显着增高。本研究提示,对于高龄患者,应根据患者具体情况谨慎确定抗凝治疗方案,必要时降低抗凝治疗强度和(或)减少抗血小板药物剂量并缩短疗程,不宜简单的套用一般成年人的治疗原则。

伴认知功能减退的老年糖尿病患者的血糖控制强度

近10年来,糖尿病患者的血糖管理策略发生显着变化,从较早的强化降糖策略逐渐转变为个体化血糖管理策略。这一策略的核心理念是根据患者具体情况确定不同的降糖目标值:对于糖尿病病史较短、年龄较轻、无明显靶器官损害、无严重低血糖事件史、预期寿命较长的患者,可以将HbA1c控制在<7.0%以下甚至更低;对于病史较长、年龄较大、已发生明显靶器官损害、曾发生严重低血糖事件、预期寿命较短者,应放松血糖控制目标。然而在临床实践中,临床医生往往忽略这一问题,很多老年糖尿病患者仍然接受了较为激进的降糖治疗。本年度内发表的一项以退伍军人为对象的大型观察性研究,旨在了解真实世界中老年人的血糖控制情况。该研究以15 880例年龄≥65岁的糖尿病伴痴呆患者为对象,结果发现52%的受试者血糖控制过于严格(HbA1c<7.0%)。 这一研究结果对于我国临床实践同样有重要启示,提示我们对于老年糖尿病患者、特别是存在认知功能减退的患者,应及时调整降糖治疗强度,适度放松血糖控制目标,避免因为过于激进的降糖治疗对患者产生不良影响。

少量运动即可降低老年人死亡率

规律性体力运动对于降低心血管疾病及其危险因素风险至关重要。现行指南一般建议成年人每周中等强度运动150分钟。由于老年人体能减退,体力活动明显减少,对于其体力活动量的设定尚存在争议。新近发表的一项荟萃分析表明,将老年人运动时间减少一半,即可使死亡风险降低22%。这项荟萃分析共纳入835项研究、涉及122 417例受试者,随访时间约10年。结果发现,与很少运动的受试者相比,每周运动量为1~499当量分钟、500~999当量分钟、≥1000当量分钟的受试者死亡率分别降低22%、28%、35%,其中心脏疾患与卒中死亡的降低最为显着。鉴于老年人常存在多种疾患,盲目提倡大量运动可能会增加不良事件风险,并会导致疼痛与过度疲劳等不良结果。该研究的主要完成人认为,对于≥60岁的老年人,不宜强调每周150分钟的运动方案,因为每周运动75分钟即可使患者显着获益。

ACTION注册研究

很多研究业已证实,老年急性心肌梗死患者接受康复训练有助于改善临床预后,但关于训练频度与预后的关系以及老年心肌梗死患者接受康复训练的最佳次数尚缺乏充分研究。本研究以急性冠状动脉治疗干预结局网络注册(Acute Coronary Treatment Intervention Outcomes Network Registry,ACTION)数据库中患者为对象,对此问题进行探讨。共纳入11 862例接受康复训练的老年急性心肌梗死患者,并进行为期1年的随访。分析结果显示,全部受试者平均康复训练次数为26次。与康复训练次数<25次的患者相比,康复次数≥26次者坚持服用二级预防药物(如抗血小板药物、β受体阻滞剂等)的依从性更优。康复次数每增加5次,死亡率降低13%,不良心脏事件发生率降低31%,死亡与再住院事件发生率降低21%。本研究结果显示,老年急性心肌梗死后患者坚持康复训练有助于改善临床预后,并且训练次数越多,患者获益越大。这项研究有力论证了老年心肌梗死患者长期坚持康复训练的重要价值。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644464, encodeId=c47f16444647a, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jul 16 19:54:00 CST 2016, time=2016-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56484, encodeId=3d16564847a, content=分享指南?, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Tue Jan 12 23:44:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54800, encodeId=00a0548004e, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54801, encodeId=0e53548016c, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54488, encodeId=7f0654488f4, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54489, encodeId=7cf754489be, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54490, encodeId=5d3a5449015, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54491, encodeId=0c8654491c6, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644464, encodeId=c47f16444647a, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jul 16 19:54:00 CST 2016, time=2016-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56484, encodeId=3d16564847a, content=分享指南?, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Tue Jan 12 23:44:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54800, encodeId=00a0548004e, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54801, encodeId=0e53548016c, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54488, encodeId=7f0654488f4, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54489, encodeId=7cf754489be, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54490, encodeId=5d3a5449015, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54491, encodeId=0c8654491c6, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-01-12 Lynee劲飞扬

    分享指南?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1644464, encodeId=c47f16444647a, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jul 16 19:54:00 CST 2016, time=2016-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56484, encodeId=3d16564847a, content=分享指南?, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Tue Jan 12 23:44:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54800, encodeId=00a0548004e, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54801, encodeId=0e53548016c, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54488, encodeId=7f0654488f4, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54489, encodeId=7cf754489be, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54490, encodeId=5d3a5449015, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54491, encodeId=0c8654491c6, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-01-09 medsic

    好棒,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1644464, encodeId=c47f16444647a, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jul 16 19:54:00 CST 2016, time=2016-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56484, encodeId=3d16564847a, content=分享指南?, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Tue Jan 12 23:44:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54800, encodeId=00a0548004e, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54801, encodeId=0e53548016c, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54488, encodeId=7f0654488f4, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54489, encodeId=7cf754489be, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54490, encodeId=5d3a5449015, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54491, encodeId=0c8654491c6, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-01-09 medsic

    好棒,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1644464, encodeId=c47f16444647a, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jul 16 19:54:00 CST 2016, time=2016-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56484, encodeId=3d16564847a, content=分享指南?, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Tue Jan 12 23:44:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54800, encodeId=00a0548004e, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54801, encodeId=0e53548016c, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54488, encodeId=7f0654488f4, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54489, encodeId=7cf754489be, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54490, encodeId=5d3a5449015, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54491, encodeId=0c8654491c6, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-01-08 medsic

    谢谢分享!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1644464, encodeId=c47f16444647a, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jul 16 19:54:00 CST 2016, time=2016-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56484, encodeId=3d16564847a, content=分享指南?, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Tue Jan 12 23:44:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54800, encodeId=00a0548004e, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54801, encodeId=0e53548016c, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54488, encodeId=7f0654488f4, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54489, encodeId=7cf754489be, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54490, encodeId=5d3a5449015, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54491, encodeId=0c8654491c6, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-01-08 medsic

    谢谢分享!!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1644464, encodeId=c47f16444647a, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jul 16 19:54:00 CST 2016, time=2016-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56484, encodeId=3d16564847a, content=分享指南?, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Tue Jan 12 23:44:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54800, encodeId=00a0548004e, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54801, encodeId=0e53548016c, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54488, encodeId=7f0654488f4, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54489, encodeId=7cf754489be, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54490, encodeId=5d3a5449015, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54491, encodeId=0c8654491c6, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-01-08 medsic

    谢谢分享!!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1644464, encodeId=c47f16444647a, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Jul 16 19:54:00 CST 2016, time=2016-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56484, encodeId=3d16564847a, content=分享指南?, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160113/IMG569619FEB03536446.jpg, createdBy=85f81678980, createdName=Lynee劲飞扬, createdTime=Tue Jan 12 23:44:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54800, encodeId=00a0548004e, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54801, encodeId=0e53548016c, content=好棒,, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 09:54:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54488, encodeId=7f0654488f4, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54489, encodeId=7cf754489be, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54490, encodeId=5d3a5449015, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=54491, encodeId=0c8654491c6, content=谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Fri Jan 08 10:36:00 CST 2016, time=2016-01-08, status=1, ipAttribution=)]
    2016-01-08 medsic

    谢谢分享!!

    0

相关资讯

Nutrients:地中海饮酒方式能降低心血管疾病发生的风险吗?

背景:整体饮酒模式而不是饮酒量对心血管疾病(CVD)发生的影响尚不清楚,研究者对其进行评估。方法:研究者对14651名受试者,随访了14年。建立了评估饮酒模式的7个维度,符合传统的地中海饮酒模式(MADP)。这七个维度为,适度饮酒,每周间隔酒精摄入,低烈酒消耗,喜欢白酒,喝红酒,餐间饮酒及避免暴饮。结果:随访的142177人-年中,127例CVD事件发生(心肌梗死,卒中或心血管死亡)。与符合MAD

Stroke:达比加群不会增加亚洲非瓣膜性房颤患者的心血管疾病、出血等风险

在非瓣膜性房颤亚洲患者中,与达比加群相关的心血管疾病,出血事件和死亡率的不同风险,是否不同于华法林所导致的这些风险呢?这些疑问目前还不清楚。研究人员使用了台湾全民健康保险研究资料库,获得了在2012年6月1日至2013年12月31日之间分别服用达比加群和华法林的9940例和9913例非瓣膜性房颤患者的资料,研究人员将其作为动态队列。研究人员使用倾向得分加权治疗逆概率来平衡2个研究组的协变量。患者被

BMJ Open:禁烟令对心血管和呼吸系统疾病的影响评估

目的:最近的研究已经评估了烟草法对心血管和呼吸系统疾病发病率的影响。在这项研究中,研究者研究,校正混杂因素后,西班牙的2005禁烟令的实施和因心血管和呼吸道疾病住院是否相关。设计:生态时间序列分析。设置:马德里和巴塞罗那市(西班牙)的居民。从2003-2006年西班牙住院登记中筛选出日常急救室接诊的急性心肌梗死,脑血管疾病、慢性阻塞性肺疾病(COPD)和哮喘患者。方法:应用附加Poisson模型评

肠道微生物又上头条了!看克利夫兰诊所在《cell》上的发文

现实生活中,人们总是难以抵制脂肪的诱惑,因为它是如此的爽滑鲜香。有人辩解说,人类嗜脂肪是基因对远古饥饿的记忆造成的。现在饥饿终于不再缠着我们了,可是心血管疾病却找上了门。据WHO统计,每年大约有1750万人死于心血管疾病,竟占到全年死亡总人数的三分之一。众所周知,动脉粥样硬化是心血管疾病发作的主要因素之一。而高脂饮食恰恰是动脉粥样硬化的罪魁祸首。最近有研究表明,动脉粥样硬化背后的“主谋”之一竟是肠

JACC:以运动为基础的心脏康复可降低心血管疾病死亡率

虽然建议使用冠状动脉心脏疾病(CHD)的管理准则,但人们对于从运动锻炼为主的心脏康复(CR)现有的荟萃分析证据的适用性已经产生了质疑。

Am J Clin Nutr:脂肪怎么吃,才健康

背景:膳食中脂肪质量和脂肪替代品的摄入对心血管疾病的预防比膳食脂肪摄入总量更为重要。目标:目的是评估总的脂肪摄入量和脂肪类型与心血管疾病(CVD)风险(心肌梗死、中风或心血管死亡),心血管疾病死亡和全因死亡之间的相关性和心血管死亡和全因死亡。研究者检验了一个假设:大量营养素的热量可相互替代。设计:从PREDIMED研究中,研究者前瞻性地研究了7038名高CVD风险的患者。试验是从2003到2010